FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

202289 citationsJournal Article

Authors

Ralf‐Dieter Hofheinz · Heidelberg University

Kirsten Merx · Heidelberg University

Georg Martin Haag · Heidelberg University

Christoph Springfeld · Heidelberg University

Thomas J. Ettrich · University Hospital Ulm

K Borchert · University Hospital Magdeburg

Albrecht Kretzschmar

Abstract

The addition of trastuzumab/pertuzumab to perioperative FLOT significantly improved pCR and nodal negativity rates at the price of higher rates of diarrhea and leukopenia.

Topics & Keywords

Gastric Cancer Management and Outcomes Gastrointestinal Tumor Research and Treatment Metastasis and carcinoma case studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 40, Issue 32, pp. 3750-3761

DOI: 10.1200/jco.22.00380

Field-Weighted Citation Impact: 12.79